Infecciones invasivas por Streptococcus pneumoniae en un hospital pediátrico de tercer nivel antes de la introducción de la vacuna conjugada: Características clínicas y serotipos involucrados

Invasive pneumococcal diseases are the main cause of morbidity and mortality in children. In the Hospital “Prof. Dr. Juan P. Garrahan”, between October 1 st , 2008 and September 30 th , 2011 all invasive pneumococcal diseases with positive blood cultures were retrospectively studied before the implementation of the universal immunization schedule with the 13-valent pneumococcal conjugate vaccine. A total of 124 patients were identified, and their mean age was 48.3 months (range: 1-216). In this population, 58.9% (n: 73) were OVER 2 years old and 89% (n: 65) of them had an underlying disease. The most frequent clinical presentation was pneumonia. The most frequent S. pneumoniae serotypes identified were: 14 (22.5%, n: 25), 6 (14.4%, n: 16), 19 (8.1%, n: 9), 23 (7.2%, n: 8), 1 (6.3%, n: 7), 5 (4.5%, n: 5), and 7 (7.2%, n: 8). Of the S. pneumoniae serotypes in this series, 82.2% is included in the 13-valent pneumococcal conjugate vaccine. Continuous epidemiological surveillance is essential to further identify the epidemiology and study the evolution of invasive pneumococcal disease in Argentina.

[1]  A. Lassen,et al.  Bacteremia with Streptococcus pneumoniae: sepsis and other risk factors for 30-day mortality—a hospital-based cohort study , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[2]  C. Byington,et al.  The Changing Epidemiology of Invasive Pneumococcal Disease at a Tertiary Children's Hospital Through the 7-valent Pneumococcal Conjugate Vaccine Era: A Case for Continuous Surveillance , 2012, The Pediatric infectious disease journal.

[3]  C. Muñoz-Almagro,et al.  Clinical Presentation of Invasive Pneumococcal Disease in Spain in the Era of Heptavalent Conjugate Vaccine , 2012, The Pediatric infectious disease journal.

[4]  John S. Bradley,et al.  The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  S. Kaplan,et al.  Serotype 19A Is the Most Common Serotype Causing Invasive Pneumococcal Infections in Children , 2010, Pediatrics.

[6]  K. Auranen,et al.  Estimation of vaccine efficacy against acquisition of pneumococcal carriage. , 2009, Vaccine.

[7]  L. Bricks,et al.  Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases. , 2006, Jornal de pediatria.

[8]  Pascal Peeters,et al.  LOW IMMUNOLOGIC RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN NAIVE VERTICALLY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CHILDREN WITH SEVERE IMMUNODEFICIENCY , 2006, The Pediatric infectious disease journal.

[9]  Tamara Pilishvili,et al.  Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.

[10]  S. Kaplan,et al.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. , 2004, Pediatrics.

[11]  E. McIntosh,et al.  How many episodes of hospital care might be prevented by widespread uptake of pneumococcal conjugate vaccine? , 2003, Archives of disease in childhood.

[12]  C. Feldman,et al.  Streptococcus pneumoniae respiratory tract infections. , 2001, Current opinion in infectious diseases.